New hope for rare tumors? drug axitinib tested in small trial
NCT ID NCT03839498
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests the drug axitinib in 6 adults with metastatic or inoperable pheochromocytoma or paraganglioma, rare tumors of the adrenal glands or nerve tissue. Axitinib works by blocking blood vessel growth that feeds tumors. The main goal is to see how many patients' tumors shrink or stop growing. Researchers will also track how long the disease stays under control and study genetic factors that might affect response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Axitinib (a drug that blocks blood vessel growth to tumors)
What this could lead to
If it works, this could point toward a new treatment option for people with rare adrenal or nerve tumors that have spread.
What could go wrong
This is a very small, early-phase study with only 6 participants, so results may not apply widely. The drug may not shrink tumors or could cause side effects like high blood pressure or fatigue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHEOCHROMOCYTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Irving Medical Center
New York, New York, 10031, United States